click enter text
full postview revenu in-lin ep beat
report financi result morn revenu
in-lin consensu ep beat rais ep guidanc
maintain full-year humira guidanc guid revenu
ex-u y/i oper still maintain
year intern eros around
bodi report full analysi
recent in-depth discuss pipelin see recap
addit detail us/eu drug compani cover
see global pharmaceut april issu monthli controversi
trade fundament data
upsid target
factset/wolf research price april
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
thursday open
report result in-lin consensu revenu beat ep
maintain guidanc revenu rais ep midpoint
overal impress report quiet set result solid key product
track well confer call usual provid mani addit element guidanc beyond
given press releas natur major import humira verbal guidanc
expect sale appear slightli analyst forecast vs estim guid
us growth vs intern guid sale around slightli
estim element guidanc may led sell-off confer call
apart much els pivot said assur good market access newly-
approv skyrizi note everi psoriasi patient choos skyrizi vs humira make less
money royalti pay boehring ingelheim skyrizi royalti level disclos
knowledg overal stori remain view near- intermediate-term perform
competit real concern financi look like period humira face
us biosimilar competit model begin deviat substanti consensu downsid
long-term period believ abbv core abil weak current late-stag pipelin
capabl provid enough off-set stem declin arguabl abbv price-to-earnings multipl low
alreadi reflect mani challeng dividend yield presum help put floor
share price remain like path forward bolster long-term growth view
matter time
recent in-depth discuss pipelin see recap pipelin unplug call
addit detail us/eu drug compani cover see
april issu monthli controversi report
term sale ep exhibit
revenu report sale vs estim consensu
ep report non-gaap ep vs estim consensu
humira sale vs consensu remind first full quarter
biosimilar impact reflect abbv financi result imbruvica sale vs consensu
hcv sale vs consensu venclexta sale vs
consensu
revenu maintain prior level oper flat y/i fx
page
humira maintain fy guidanc guid ex-u revenu signal y/i decreas
oper quarter
ep rais vs prior increas
revenu decreas ep increas
revenu estim chang ep estim chang
depend year
ep compound-annual-growth-rate ep compound-annual-growth-rate decreas slightli vs prior repres
peer averag growth peer average compound-annual-growth-rate
price target unchang repres unchang multipl new
reaffirm fy revenue growth cc fx impact gm around op margin higher
prior year guidanc element unchang expect ep rev
fx impact humira us intern imbruvica sale approach
op margin
 rais guidanc sign confid often done past
one time benefit gm done guidanc increas three time past
often occur later quarter gm side termin royalti payment humira one
boost mani item impact one-tim basi
 updat thought continu look asset realli chang assess
 confid prior op margin guidanc process lrp give
updat guidanc time continu see increas leverag howev
 regard healthcar reform expect rebat rule propos
note goal realli provid patient better access medicin alreadi
extens pap help rebat chang maintain would impact
compani realli provid materi new inform insight abl handicap
pass doesnt
page
eu eros in-lin expect
 abbv humira guidanc seem suggest greater eros investor expect
comment say recent eros guidanc total intern base
remain comfort vari countri ge may higher
aggress biosimilar thu far later say
guidanc impli oper declin ex-u
 elabor y/i eros guidanc ex-u say look guidanc
compar intern sale prior year would oper declin
expect commerci access end juli psoriasi achiev psoriasi drug launch
believ best class profil recount highlight drug efficaci dose
profil quarterli full year expect sale mostli
 sort ramp expect rel histor launch posit rel
humira psoriasi product histor market access slower
case skyrizi note use free good extens keep sale level
lower side overal expect better ramp vs histor product rel humira skyrizi
better data posit front-lin agent expect humira slow somewhat diseas
 discuss slightli higher rate immunogen point clinic data show
robust efficaci doesnt believ immunogen concern
venvlexta mm still believ path forward select mm patient imbruvica new patient
share cll
 hypothesi venclexta issu mm admit surpris find sure
drove cll driver diseas mm driver work fda
partial clinic hold
uterin fibroid indic remain track submit applic mid
 launch go maintain go expect recept good posit
feedback patient also encourag even dose patient see rapid relief pain start
dtc coupl month ago track run rate grow comfort full-year guidanc
product
page
remain track us regulatori decis
 expect fda adcom view safeti class light xeljanz
data say adcom common nme like would surpris present
actual anticip one regard xeljanz remind safeti data
dose approv ra popul higher risk cv event well cant say
much seen full data
 product interest early- mid-stag pipelin call egfr-
target gbm deliv interest earlier data os primari endpoint
call earli work apoptosi also highlight next-gen venetoclax broader activ includ
myelofibrosi io done lot work tau antibodi mention earlier
page
exhibit show compani report actual result vs estim consensu
exhibit abbvi result vs wr estim consensu
page
exhibit summar financi guidanc vs estim
exhibit abbvi guidanc vs wr estim old new
page
oldnewoldnewtot revenuesgrow op marginabov saleshigh marginjust interest exp approach tax ratejust tax guidancewr estim
exhibit captur chang forecast
exhibit chang wr model
page
exhibit show incom statement product revenu summari balanc sheet/cash flow
page
incom statement oper expens foreign exchang incom expens outstand margin total profit profit profit incom growth oper
page
product revenu earli phase total
exhibit wr balanc sheet cash flow statement
page
flow statement incom intang chang oper asset flow oper activ busi net cash acquisit properti flow invest activ chang short-term issuanc lt lt debt leas treasuri flow financ activ fx cash increas decreas cash sheet cash properti plant goodwil current term non-curr stock held paid-in comprhens sharehold liabil sharehold
